Lerodalcibep is a medicine used to lower LDL ("bad") cholesterol in adults with high cholesterol. It is given as a shot under the skin once a month. It works by helping the liver clear more bad cholesterol from the blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Lerochol (Lerodalcibep) for High Cholesterol (Hypercholesterolemia)?
Lerodalcibep, sold as Lerochol, is a once-monthly injection that lowers low-density lipoprotein (LDL) cholesterol, the "bad" cholesterol that builds up in artery walls and raises the risk of heart attack and stroke. It is approved for adults with high cholesterol, including heterozygous familial hypercholesterolemia (HeFH), an inherited condition that keeps LDL high from birth. It is used alongside diet and exercise, and in its studies it was added to the highest statin dose each person could tolerate when that was not enough on its own. Lerochol belongs to a group of medicines that block a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9). These PCSK9 inhibitors also include Repatha (evolocumab) and Praluent (alirocumab). The US Food and Drug Administration (FDA) approved it in December 2025. Its approval rests on how much it lowers LDL cholesterol: it has not yet been shown in a study to reduce heart attacks or strokes, as Repatha and Praluent have. It is not approved for children.
The liver clears LDL cholesterol from the blood using receptors on its cells that grab LDL particles and pull them inside. A protein called PCSK9 tags those receptors for destruction, so the more PCSK9 there is, the fewer receptors remain and the more LDL stays in the blood. Lerodalcibep is a lab-made protein that binds tightly to PCSK9 and stops it from reaching the receptors. More receptors survive, the liver removes more LDL, and blood levels fall. It is built by joining a small PCSK9-binding piece to albumin, a common blood protein, which helps it last long enough for monthly dosing. This approach differs from statins, which reduce how much cholesterol the liver makes, so the two can be combined.
Lerochol comes as a single-dose prefilled syringe containing 300 mg, injected under the skin once a month. People can inject it themselves into the abdomen or the front of the thighs after training from the care team; a caregiver or health professional can also use the back of the upper arm. Rotating sites and avoiding skin that is tender, bruised or red helps. The full dose is given by pushing the plunger until the syringe is empty. The syringes are stored in the refrigerator, but one can be kept at room temperature (up to 77°F) in its carton for up to three months, which makes travel easier. A refrigerated syringe should sit out for at least 30 minutes before injecting. The liquid is normally clear to slightly hazy and yellowish-brown; do not use it if it is cloudy or has particles. If a dose is missed by less than 7 days, give it as soon as possible and keep the original schedule. If it is 7 or more days late, give it as soon as possible and start a new monthly schedule from that date.
The most common side effect is a reaction where the shot was given, such as redness, pain, itching or swelling. In the main studies these affected roughly 12 to 18 out of 100 people taking Lerochol, compared with about 3 to 5 out of 100 taking a placebo, and they were the most common reason people stopped. Cold-like symptoms, diarrhea, nausea and some swelling of the legs or ankles were also reported a little more often than with placebo. Overall, side effects in the year-long studies were similar to placebo, and few people stopped treatment because of them. Some people develop antibodies to the medicine, but in the studies this did not change how well it worked or its safety. Injection site reactions that are severe, spreading or not settling are worth raising with the prescriber.
Lerochol has no listed contraindications, and no formal drug interaction studies have been done. It is usually taken together with a statin, and sometimes with ezetimibe (another cholesterol-lowering pill). The prescriber should still know every medicine and supplement being taken. Based on how it works, Lerochol may harm a developing baby. Cholesterol treatment is generally not needed during pregnancy, so the medicine is usually stopped once pregnancy is recognized, although the prescriber may weigh individual needs. Anyone who is pregnant, planning pregnancy or breastfeeding should discuss it; it is likely to pass into breast milk, and there are no human data on the effects. Lerochol has not been studied in people with severe kidney disease or severe liver disease.
The medicine blocks PCSK9 within a day of the first injection, and a cholesterol blood test can show the effect from about 4 weeks on. In the main studies, adding Lerochol to a statin lowered LDL by roughly half compared with placebo after a year, and by about 59 percent compared with placebo in people with HeFH. Individual results vary, and the care team will use follow-up cholesterol tests to judge whether it is enough. There is nothing to feel when LDL falls, so the benefit shows up only in test results. Lowering LDL is the goal because high LDL drives artery damage over years, but the effect depends on staying on monthly doses, since the medicine's hold on PCSK9 fades toward the end of each month. For most people this is long-term treatment, used together with a statin, diet and exercise.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lerochol (Lerodalcibep), what you've noticed, or ask the community a question.